Axsome bounces back as FDA clears depression drug
pharmaphorum
AUGUST 21, 2022
The FDA has cleared Auvelity (dextromethorphan/bupropion) for the treatment of major depressive disorder (MDD) in adults, setting up a launch in the fourth quarter of this year. However, it has a broader label as unlike J&J’s drug it is indicated for use in previously-untreated MDD.
98 
Let's personalize your content